Metabolic and Body Composition Research Track
The compounds behind the fat-loss results everyone is talking about.
Users report significant weight loss on GLP-1 compounds. Here is what they report, what the trials prove, and which compounds are approved versus experimental.
Who this is for
Fat loss, glucose regulation, appetite, energy metabolism, mitochondrial signaling, body composition, insulin sensitivity.
How this track is graded
Metabolic compounds span the widest evidence gap in the space, from FDA-approved drugs with large human trials to early research compounds with only preclinical data. This track sorts them so you always know which tier you are looking at.
Snapshot
| Compound | Tier | What people research it for | What the evidence shows |
|---|---|---|---|
| Semaglutide | A | Users report major appetite reduction and weight loss. | Strong human trials. FDA approved. |
| Tirzepatide | A | Users report faster and larger weight loss than single agonists. | Strong human trials. FDA approved. |
| Retatrutide | B+ | Trial participants report strong weight loss. | Strong phase 2 and 3 data. Not FDA approved. |
| AOD-9604 | B | Researched for lipolysis. | Did not reach obesity-drug efficacy in trials. |
| MOTS-C | B | Mitochondrial and metabolic signaling. | Mostly preclinical. |
| 5-Amino-1MQ | C | NNMT inhibition for adipose metabolism. | Preclinical only. |
| SLU-PP-332 | C | Exercise-mimetic mitochondrial signaling. | Preclinical only. |
Pressure Test · Lead compound
Semaglutide
Mechanism
GLP-1 agonist.
Evidence
Tier A. Strong human trials.
Risk
Medical supervision required. GI effects.
Standing
FDA approved for specific indications.
Comparisons
Coming
- MOTS-c vs AOD-9604
- 5-Amino-1MQ vs SLU-PP-332
Download the Peptide Research Playbook
Stop guessing. Learn how to evaluate peptide claims before you trust them.
Free Peptide Research Playbook on signup. No spam. Unsubscribe anytime.